摘要:
Natural and modified neurotoxins and isolated neurotoxin compositions are described. The neurotoxins may include one or more structural modifications, wherein the structural modification(s) alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification(s). In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.
摘要:
The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xDxxxLL (SEQ ID NO: 111) at the C-terminus, wherein x is any amino acid.
摘要翻译:本发明涉及包含E型肉毒杆菌毒素的修饰轻链的毒素,其中所述修饰的轻链在N-末端包含氨基酸序列PFVNKQFN(SEQ ID NO:120)和氨基酸序列xDxxxLL(SEQ ID NO: NO:111),其中x是任何氨基酸。
摘要:
The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.
摘要翻译:本发明涉及包含E型肉毒杆菌毒素修饰轻链的毒素,其中所述修饰的轻链包含在N末端的氨基酸序列PFVNKQFN(SEQ ID NO:120)和氨基酸序列xExxxLL(SEQ ID NO: NO:112),其中x是任何氨基酸。
摘要:
The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xDxxxLL (SEQ ID NO: 111) at the C-terminus, wherein x is any amino acid.
摘要翻译:本发明涉及包含E型肉毒杆菌毒素的修饰轻链的毒素,其中所述修饰的轻链在N-末端包含氨基酸序列PFVNKQFN(SEQ ID NO:120)和氨基酸序列xDxxxLL(SEQ ID NO: NO:111),其中x是任何氨基酸。
摘要:
The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.
摘要翻译:本发明涉及包含E型肉毒杆菌毒素修饰轻链的毒素,其中所述修饰的轻链包含在N末端的氨基酸序列PFVNKQFN(SEQ ID NO:120)和氨基酸序列xExxxLL(SEQ ID NO: NO:112),其中x是任何氨基酸。
摘要:
The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.
摘要翻译:本发明涉及包含E型肉毒杆菌毒素修饰轻链的毒素,其中所述修饰的轻链包含在N末端的氨基酸序列PFVNKQFN(SEQ ID NO:120)和氨基酸序列xExxxLL(SEQ ID NO: NO:112),其中x是任何氨基酸。
摘要:
The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 144) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.
摘要翻译:本发明涉及包含E型肉毒杆菌毒素的修饰轻链的毒素,其中所述修饰的轻链在N-末端包含氨基酸序列PFVNKQFN(SEQ ID NO:144)和氨基酸序列xExxxLL(SEQ ID NO: NO:112),其中x是任何氨基酸。
摘要:
Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.
摘要:
Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.